mrna

SM-102 is the only ionizable amino cationic lipid currently clinically approved for RNA therapeutics and can be used to synthesize lipid nanoparticles (LNPs). It shows potential in the development of LNPs for the delivery of mRNA-based vaccines.

Cannabigerol is a high affinity α±2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist ; also binds to the CB2 receptor; it can relieve interocular pressure, which may be of benefit in the treatment of glaucoma.

The COVID-19 Spike Protein mRNA, responsible for expressing the COVID-19 spike protein, is crucial for evaluating RNA delivery, translation efficiency, and cell viability. Positioned on the membrane surface, this spike protein facilitates virus entry into cells by binding to host cell membrane receptors and promoting membrane fusion. It serves as a significant action site for neutralizing antibodies and represents a primary focus in vaccine development [1].

CD19 car mRNA-LNP, a lipid nanoparticle (LNP) encapsulating CD19 car mRNA, is instrumental in assessing RNA delivery, translation efficacy, and cell viability among other applications. This compound is pivotal for chimeric antigen receptor T cell immunotherapy (CAR-CD19), leveraging the CD19 molecule - a critical membrane antigen expressed by B cells (i.e., leukocyte differentiation antigen) that plays a significant role in their proliferation, differentiation, activation, and antibody production, as well as enhancing BCR signal transduction [1] [2].

mRNA-Encapsulating Lipid Excipient 1 (Compound 2), a thiocarbamate-based ionizable lipid, serves as an excipient in the formulation of mRNA-encapsulating lipid nanoparticles [1].

COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) formulated with the novel coronavirus pneumonia spike protein, positioned on the membrane surface. It is designed for applications such as RNA delivery, translation efficiency, and cell viability assessment. This spike protein facilitates the COVID-19 virus's entry into host cells by binding to cell membrane receptors and enabling membrane fusion, making it a critical focal point for host neutralizing antibodies and vaccine development [1].

eGFP mRNA-LNP is a lipid nanoparticle encapsulating eGFP mRNA, designed to evaluate RNA delivery, translation efficiency, and cell viability. Upon cell internalization, it expresses Enhanced Green Fluorescent Protein (eGFP), enabling detection through fluorescence microscopy or flow cytometry [1].

eGFP mRNA-LNP (500 ng uL) is a lipid nanoparticle (LNP) containing eGFP mRNA, suitable for assays of RNA delivery, translation efficiency, and cell viability. eGFP circRNA includes the Enhanced Green Fluorescent Protein (eGFP), which expresses green fluorescent protein upon entering cells. eGFP is commonly used as a reporter gene detectable by fluorescence microscopy or flow cytometry.

CD19 CAR mRNA is designed to express the CD19 chimeric antigen receptor (CAR) protein, pivotal in chimeric antigen receptor T cell (CAR-CD19) immunotherapy. This receptor targets CD19, a membrane antigen crucial for B cell proliferation, differentiation, activation, and antibody synthesis, playing a significant role in promoting BCR signal transduction.

C12-200 is a benchmark ionizable cationic lipidoid along with helper lipids and can be used in the delivery of mRNA.

NF-κΒ activator 1 can activate the nf-kappa Β gene activator, EC50 of 0.9 microns. NF-κΒ is widely used in eukaryotic cells as a gene regulating cell proliferation and cell survival. NF-κΒ activator 1 induces superoxide dismutase (SOD) 2 1 mRNA expression.

TVB-3664 is an orally active, selective, reversible, and highly bioavailable fatty acid synthase inhibitor (FASN) with an IC50 for palmitate synthesis of 18 nM in human and 12 nM in mouse.Significantly inhibits microtubule protein palmitoylation and mRNA expression.

ALC-0315 is an ionizable amino lipid that has been used in combination with other lipids to form lipid nanoparticles. Lipid-Nanoparticles have been used in the research of mRNA COVID-19 vaccine

Risdiplam (RG7916) is a centrally and peripherally distributed and orally administrable small molecule SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels.

B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.

KYN-101 is an orally active and selective aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity. KYN-101 decreases CYP1A1 mRNA expression and can be used in the study of breast cancer and acute myeloid leukemia. KYN-101 is an orally active and selective aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity.

Sinefungin (Adenosyl-Ornithine) is an effective inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viral multiplication. Sinefungin is a SET7 9 inhibitor and ameliorates renal fibrosis by inhibiting H3K4 methylation.

Diethylnorspermine HCl (N1,N11-Diethylnorspermine tetrahydrochloride) potently induces SSAT (spermidine spermine N1-acetyltransferase) mRNA and effectively stabilizes SSAT enzyme activity.

Abaperidone is a potent 5-HT2A receptor and dopamine D2 receptor antagonist with an IC50 of 6.2 for 5-HT2A receptors and 17 nM for dopamine D2 receptors.Abaperidone is a potentially atypical anti-psychotropic compound that reduces basal hsp70 mRNA expression in rat striatum and prefrontal cortex. expression in the striatum and prefrontal cortex of rats.

safironil is a novel antifibrotic compound and a competitive inhibitor of collagen synthesis. safironil inhibited in vitro experiments on fibroblast activation monitored by collagen I mRNA or smooth muscle alpha-actin levels, and fibrogenesis as judged by type I and type III collagen and laminin production. safironil had no effect on the size of liver granulomas without altering total hydroxyproline, but altered the pattern of fibrosis by increasing type III and decreasing type I collagen deposition.

FY-21 is a selective LSD1 inhibitor (IC50= 340 nM) that inhibits proliferation and colony formation of leukemia cells, decreases mRNA levels of the transcription factors HOXA9 and MEIS1, and can be used in the study of leukemia.

FT001 is a potent, selective and orally available inhibitor of BET Bromodomain with antitumor activity. FT001 inhibited the expression of MYC with the IC50 value of 0.46 μM). FT001 has potent antiproliferative effects against MV-4-11 and demonstrates significant MYC mRNA suppression both in vitro and in vivo.

CJ-13,610 is an orally active and nonredox-type inhibitor of 5-lipoxygenase (5-LOX). CJ-13,610 inhibits the biosynthesis of leukotriene B4 and regulates the expression of IL-6 mRNA in macrophages.

Temarotene (Ro 15-0778) is an orally active and potent small molecule compound that modulates human immune function in vitro.Temarotene may be used in the study of lichen planus.